InFocus Clinical Research today announced it has been ranked No. 434 on the 2025 Inc. 5000 list, a significant leap from its position at No. 724 in 2024. The Inc. 5000 recognizes the fastest-growing ...

ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And DoneTM ...

We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust interest from retina specialists and ...

Target Audience The intended audience for the activity is US-based ophthalmologists, retina specialists, and optometrists involved in the management of retinal diseases.

ANI Pharmaceuticals' Q2 2025 earnings report highlights record revenues, strong Cortrophin Gel demand, and raised guidance.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...